Lake Street analyst Thomas Flaten has reiterated a 'Buy' rating for AEON Biopharma and increased the price target from $1 to $2. This indicates a positive outlook from the analyst, suggesting potential upside for the stock based on their research.
This 8-K filing discloses that Lake Street analyst Thomas Flaten has maintained a 'Buy' rating on AEON Biopharma and raised the price target from $1 to $2. This is a positive development for AEON as it signals increased confidence from a research firm, potentially attracting more investor interest. While not a direct company action, an analyst upgrade and price target increase can influence short-term trading sentiment and potentially lead to a modest price bump. For traders, this presents an opportunity to consider AEON, though the long-term implications depend on the company's fundamental performance and future developments. The key risk is that analyst ratings are opinions and do not guarantee future stock performance.